Patient demographics and clinical characteristics
| . | All patients (N = 66) . | t(11;14) (n = 30) . | Non-t(11;14) (n = 36) . |
|---|---|---|---|
| Age, median (range), years | 63 (31-79) | 63 (31-77) | 64 (41-79) |
| Male, n (%) | 30 (46) | 18 (60) | 12 (33) |
| White, n/N (%) | 59/63 (94) | 28/29 (97) | 31/34 (91) |
| Time from MM diagnosis to study entry, median (range), months | 71 (11-185) | 50 (12-178) | 79 (11-185) |
| ISS stage, n/N (%) | |||
| Stage I | 24/63 (38) | 10/27 (37) | 14 (39) |
| Stage II or III | 39/63 (62) | 17/27 (63) | 22 (61) |
| Cytogenetic abnormalities, n (%) | |||
| t(4;14) translocation | 6 (9) | 0 | 6 (17) |
| 17p deletion | 12 (18) | 5 (17) | 7 (19) |
| 13q deletion | 32 (48) | 11 (37) | 21 (58) |
| Hyperdiploid | 27 (41) | 8 (27) | 19 (53) |
| Prior therapies,*n (%) | |||
| No. of prior therapies, median (range) | 5 (1-15) | 5 (1-10) | 5 (1-15) |
| Autologous stem cell transplant | 50 (76) | 21 (70) | 29 (81) |
| Bortezomib | 62 (94) | 28 (93) | 34 (94) |
| Refractory | 46 (70) | 22 (73) | 24 (67) |
| Lenalidomide | 62 (94) | 27 (90) | 35 (97) |
| Refractory | 51 (77) | 23 (77) | 28 (78) |
| Bortezomib/lenalidomide refractory | 40 (61) | 20 (67) | 20 (56) |
| Carfilzomib | 25 (38) | 13 (43) | 12 (33) |
| Refractory | 20 (30) | 11 (37) | 9 (25) |
| Pomalidomide | 39 (59) | 21 (70) | 18 (50) |
| Refractory | 35 (53) | 19 (63) | 16 (44) |
| Refractory to last prior therapy | 52 (79) | 26 (87) | 26 (72) |
| . | All patients (N = 66) . | t(11;14) (n = 30) . | Non-t(11;14) (n = 36) . |
|---|---|---|---|
| Age, median (range), years | 63 (31-79) | 63 (31-77) | 64 (41-79) |
| Male, n (%) | 30 (46) | 18 (60) | 12 (33) |
| White, n/N (%) | 59/63 (94) | 28/29 (97) | 31/34 (91) |
| Time from MM diagnosis to study entry, median (range), months | 71 (11-185) | 50 (12-178) | 79 (11-185) |
| ISS stage, n/N (%) | |||
| Stage I | 24/63 (38) | 10/27 (37) | 14 (39) |
| Stage II or III | 39/63 (62) | 17/27 (63) | 22 (61) |
| Cytogenetic abnormalities, n (%) | |||
| t(4;14) translocation | 6 (9) | 0 | 6 (17) |
| 17p deletion | 12 (18) | 5 (17) | 7 (19) |
| 13q deletion | 32 (48) | 11 (37) | 21 (58) |
| Hyperdiploid | 27 (41) | 8 (27) | 19 (53) |
| Prior therapies,*n (%) | |||
| No. of prior therapies, median (range) | 5 (1-15) | 5 (1-10) | 5 (1-15) |
| Autologous stem cell transplant | 50 (76) | 21 (70) | 29 (81) |
| Bortezomib | 62 (94) | 28 (93) | 34 (94) |
| Refractory | 46 (70) | 22 (73) | 24 (67) |
| Lenalidomide | 62 (94) | 27 (90) | 35 (97) |
| Refractory | 51 (77) | 23 (77) | 28 (78) |
| Bortezomib/lenalidomide refractory | 40 (61) | 20 (67) | 20 (56) |
| Carfilzomib | 25 (38) | 13 (43) | 12 (33) |
| Refractory | 20 (30) | 11 (37) | 9 (25) |
| Pomalidomide | 39 (59) | 21 (70) | 18 (50) |
| Refractory | 35 (53) | 19 (63) | 16 (44) |
| Refractory to last prior therapy | 52 (79) | 26 (87) | 26 (72) |
ISS, International Staging System.
Percentages for refractory status based on total study population.